FDA approves GSK’s Blenrep for advanced multiple myeloma
pharmaphorum
AUGUST 6, 2020
However the Oncology Drug Advisory Committee (ODAC) unanimously voted in favour of approval , although the drug’s packaging will contain prominent warnings about changes in vision including severe vision loss, corneal ulcer and symptoms such as blurred vision and dry eyes. Patients also used preservative-free eye drops.
Let's personalize your content